TrueCell · A microfluidic chip for automating three-dimensional cell culture for personalized medicine
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2018-01-08 → 2020-04-12
- EU contribution
- €173,076
- Participants
- 1
- Scheme
- MSCA-IF-EF-SE
Lines connect the coordinator with its partners.
Results in brief
A microfluidic chip for automating three-dimensional cell culture for personalized medicine
Cell culture is a process which is becoming increasingly important in the fields of research and in clinics, for applications ranging from in vitro modeling, to drug testing, cell therapy, and in vitro fertilization. An important issue with cell culture is that it requires a lot of manual intervention, which makes this task time-consuming, and prone to mistakes and variability. Today there is a lack of tools to automate cell culture, without which data scientists have a hard time streamlining many of their tasks or saving precious time and ensuring the reliability and quality of their results. As cell culture moves closer to clinics and patients, ensuring a high-quality control is becoming key to ensure efficiency for scientists and safety for patients. While originally the fellowship’s objective consisted in creating a microfluidic platform to standardize 3D cell culture, it became clear that another area of cell culture could benefit more rapidly from new automation tools in a separate area of cell culture: cell imaging. A core tasks for cell culture scientists consists in imaging cells during their culture, to ensure their viability and to extract key morpho-kinetic information. As of today, a growing number of hardware equipment is being developed to automate this imaging process, generating unprecedented volumes of data that are hard to exploit. This need is particularly obvious in the field of in vitro fertilization (IVF), where embryologists image embryos as they develop in the lab prior to their implantation back in the patient. Today, IVF clinicians lack the tools to extract key information from these videos to make reliable and data-driven decisions, such as choosing the embryo with the highest chance of implantation. Through her Marie Curie fellowship, Dr. Alexandra Boussommier-Calleja has co-founded her company ImVitro, aimed at combining the power of cell imaging and artificial intelligence to tackle infertility. ImVitro aims at developing AI-based tools that help embryologists in personalizing their decisions, starting with the evaluation of embryos during their culture, so as to minimize the number of IVF cycles patients have to go through to conceive a child. Needless to say, that these tools could have a huge impact given that today one out of seven couples suffer from infertility. For them, IVF represents one of their main medical hope, which however only works 20-30% of the times. The objectives therefore became to develop a software that can take in videos of embryos and give back a score to clinicians. To that end, we first needed to create traction with clinics, to create strong partnerships with clinics, to collect data, and to fundraise. The overall goal remained for the Fellow to create a company around this vision and commercialize this product. By the end of the fellowship, the fellow had created a company, obtained a grant to accelerate the project and developed partnerships with fertility clinics.
Data: CORDIS, © European Union
Project objective
A paradigm shift in health-care towards personalized medicine is slowly under way to tailor treatments to each unique individual’s needs. A key avenue for developing this field consists in recreating in vitro models of specific body parts with cells. In particular, cells need to be placed in three-dimensions (3D) to truly recapitulate their normal environment in the body; yet current commercial assays only facilitate culture of cells in two-dimensions, which causes cells to behave very differently thus distorting the results. Microfluidic technology is ripe for facilitating this transition, but does not offer any tool to facilitate the first essential step that consists in embedding cells in gels so that they evolve in 3D inside the gel. To address this need, we propose a novel microfluidic platform that automates cell mixing with biological gels, that overcomes the challenge of mixing liquids with such different viscosities (i.e. gel and cells in liquid), and offers precise temperature control to regulate the gel formation process. This novel tool will automate a tedious procedure that is normally done manually in the lab, which will accelerate the protocol and encourage a wider practice of 3D cell culture, and guarantee the reproducibility of the gel formation around the cells. This project will enable both I and a start-up to acquire new skills in a cutting-edge field, thus driving European innovation. I will gain new expertise in becoming an independent entrepreneur and in fabricating microfluidic tools, which will complement my pre-existing deep knowledge of biological microfluidic applications. This will enable me to transition from academia to industry, from the USA to Europe, and commercialize on my own the many ideas I have been developing over my extensive career in academic research, while Elvesys who wants to enter the growing field of microfluidic cell culture, will gain an expert in 3D cell culture trained in a world-renowned academic laboratory.
Original text from CORDIS.
Participants
- ELVESYS · PARISCoordinatorFrance
Links
Data: CORDIS, © European Union
